<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146614</url>
  </required_header>
  <id_info>
    <org_study_id>02-057</org_study_id>
    <nct_id>NCT00146614</nct_id>
  </id_info>
  <brief_title>Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation</brief_title>
  <official_title>Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD)
      after non-myeloablative transplantation can be reduced by using a combination of three immune
      suppressive medication; sirolimus, tacrolimus and methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be admitted to the hospital and receive chemotherapy and stem cell
           transplant(SCT). The total duration of hospitalization for the procedure is
           approximately 8 days. Once admitted the patient will receive fludarabine daily for 4
           days, busulfex once daily for 4 days. Two days after chemotherapy has ended, the patient
           will receive the infusion of donor cells.

        -  Just prior to the transplant and following the transplant, patients will receive
           sirolimus (orally), tacrolimus (orally) and low doses of methotrexate (chemotherapy).
           Methotrexate will be given on days 1,3 and 6 after transplant.

        -  Sirolimus will be tapered beginning week 9 after transplant if there is no evidence of
           GVHD and will be eliminated on week 26 if clinically feasible.

        -  Tacrolimus will be tapered beginning week 9 after transplant if there is no evidence of
           GVHD and will be eliminated on week 26 if clinically feasible.

        -  Patients will also receive medication to help prevent possible infection.

        -  After stem cell infusion, patients will be examined and have blood tests weekly for 1
           month. At the 1 month visit, a bone marrow biopsy will performed looking for evidence of
           donor cells in the bone marrow. After the one month evaluation the patient will be
           examined every 2 weeks and a repeat bone marrow performed 3-4 months after transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect on the incidence and severity of GVHD by adding sirolimus, tacrolimus and methotrexate to GVHD prophylaxis.</measure>
  </primary_outcome>
  <enrollment>105</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematologic malignancies who are at a high risk of complications after
             conventional transplantation.

          -  Donors (both related and unrelated) who are identical at 6 HLA loci.

          -  Age greater than 18

          -  ECOG Performance Status 0-2

          -  Life expectancy of greater than 100 days.

        Exclusion Criteria:

          -  Pregnancy

          -  Evidence of HIV infection

          -  Heart failure uncontrolled by medications

          -  Total Bilirubin &gt; 2.0mg/dl due to hepatocellular dysfunction

          -  AST &gt; 90

          -  Serum creatinine &gt; 2.0

          -  Cholesterol &gt; 300 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin P. Alyea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edwin P. Alyea, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Graft versus Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

